T-ICAHT is a newly developed grading system assessing thrombocytopenia after CD19 CAR T-cell therapy, based on depth, duration, and timing.
Early (days 0-30) and late (days 31-100) thrombocytopenia are frequent, with severe cases occurring in approximately one-fifth to one-eighth of patients.
Higher T-ICAHT grades correlate with increased transfusion requirements, more bleeding events, and independently predict worse overall survival.
The grading system’s prognostic validity is confirmed across multiple hematologic malignancies, supporting its integration into the ICAHT framework.
Study Background and Disease Burden
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
